{"schema_version":"secwatch.filing_event.v1","accession":"0001082554-24-000007","form_type":"8-K","ticker":"UTHR","cik":"0001082554","company_name":"UNITED THERAPEUTICS Corp","filed_at":"2024-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.311757+00:00","generated_at":"2026-06-05T21:39:23.464685+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"United Therapeutics reports record $2.33B 2023 revenue (+20% YoY); sues FDA over Liquidia NDA amendment","bullets":["FY 2023 revenue $2.33B, net income $984.8M ($19.81 diluted EPS).","Tyvaso revenue grew 41% to $1.23B; Tyvaso DPI rose 362% to $731M.","Q4 2023 revenue $614.7M (+25% YoY), net income $217.1M (diluted EPS $4.36).","Filed lawsuit against FDA alleging agency improperly allowed Liquidia to amend pending NDA for PH-ILD, avoiding a 30-month stay of approval.","Litigation seeks to enforce Hatch-Waxman patent infringement stay pending resolution of separate patent case against Liquidia."],"urls":{"canonical":"https://secwatch.observer/filing/0001082554-24-000007","json":"https://secwatch.observer/filing/0001082554-24-000007.json","markdown":"https://secwatch.observer/filing/0001082554-24-000007.md","text":"https://secwatch.observer/filing/0001082554-24-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1082554/000108255424000007/0001082554-24-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1082554/000108255424000007/uthr-20240221.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T21:39:23.464685+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0ac8e63a3d24b3f4253de3d049387f58c2cf53f8","claim":"UNITED THERAPEUTICS Corp reported three months ended December 31, 2023 results: revenue $614.7 million, net income $217.1 million, EPS $4.36 per diluted share.","evidence_excerpt":"Key financial highlights include (in millions, except per share data): Three Months Ended December 31, Year Ended December 31, 2023 2022 2023 2022 Total revenues $ 614.7 $ 491.5 $ 2,327.5 $ 1,936.3 Net income $ 217.1 $ 132.1 $ 984.8 $ 727.3 Net income, per basic share $ 4.62 $ 2.88 $ 21.04 $ 15.98 Net income, per diluted share $ 4.36 $ 2.67 $ 19.81 $ 15.00","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1082554/000108255424000007/0001082554-24-000007-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended December 31, 2023"},{"label":"Revenue","value":"$614.7 million"},{"label":"Net income","value":"$217.1 million"},{"label":"EPS","value":"$4.36 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"2699e875f6c682b0c64a518189034920dcf27f9c","claim":"UNITED THERAPEUTICS Corp reported year ended December 31, 2023 results: revenue $2,327.5 million, net income $984.8 million, EPS $19.81 per diluted share.","evidence_excerpt":"(Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2023. Full year 2023 revenues rose to a record $2.33 billion, reflecting 20% growth over 2022. “Congratulations to the dedicated Unitherians who worked tirelessly to help us achieve our third straight quarter and second straight year of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1082554/000108255424000007/0001082554-24-000007-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2023"},{"label":"Revenue","value":"$2,327.5 million"},{"label":"Net income","value":"$984.8 million"},{"label":"EPS","value":"$19.81 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}